DorsaVi Ltd, a health care biotechnology company based in Melbourne East, Australia, has recently announced the commencement of early-stage testing for resistive‑RAM (RRAM) chips. This initiative is part of a broader strategy to develop a 22‑nanometre memory platform, which is aimed at supporting edge and ultra‑edge AI applications. The company’s efforts are focused on addressing the growing demand for advanced memory solutions driven by expanding AI workloads.
The initial test wafer, which was received at a 180‑nanometre node, will undergo evaluation for device performance, material interfaces, and manufacturability. DorsaVi’s roadmap is designed to deliver significant improvements over its current 40‑nanometre devices, including lower write voltage, reduced latency, and enhanced reliability. These advancements are expected to facilitate more efficient in‑memory and neuromorphic computing, which are critical for applications in robotics, drones, and autonomous systems.
DorsaVi has highlighted the increasing pressure on conventional memory supplies, a challenge exacerbated by the expanding AI workloads. The company’s advanced‑node RRAM is positioned as a strategic response to the “memory wall” and power constraints that currently affect modern AI accelerators. By developing this cutting-edge technology, DorsaVi aims to provide a viable solution to these pressing issues.
As part of its ongoing efforts, DorsaVi will continue to report progress as it moves toward the commercialization of the 22‑nanometre platform. The company’s focus on innovation in memory technology underscores its commitment to addressing the evolving needs of the AI and biotechnology sectors.
DorsaVi Ltd is listed on the ASX All Markets stock exchange, with a market capitalization of 32,670,772 AUD. Despite a negative price-earnings ratio of -5.78, the company’s strategic initiatives in memory technology development reflect its potential for growth and impact in the health care and biotechnology industries. For more information about DorsaVi and its offerings, interested parties can visit the company’s website at www.dorsavi.com .
